Institute of Cancer Research
The Institute of Cancer Research (the ICR) is a cancer research university located in London, United Kingdom and a constituent college of the federal University of London. It was founded in 1909 as a research department of the Royal Marsden Hospital and joined the University of London in 2003. It has been responsible for a number of breakthrough discoveries, including that the basic cause of cancer is damage to DNA. Together with the Royal Marsden Hospital the ICR forms the largest comprehensive cancer centre in Europe, and was ranked first amongst all British higher education institutions in the Times Higher Education 2008 Research Assessment Exercise Table of Excellence. In addition to its research activities the ICR provides both taught postgraduate degree programmes and research degrees and currently has around 340 students. It occupies two sites, one in Chelsea in Central London and one in Sutton in southwest London, and had a total income of £85.4 million in 2010/11, of which £50.5 million was from research grants and contracts.
A whole-genome scan to identify large-scale chromosomal damage can help doctors choose the best treatment option for children with neuroblastoma, one of the most common types of childhood cancer, finds an international collaboration ...
Cancer Sep 14, 2012 | 5 / 5 (1) | 0 |
The head of one of the UK's leading cancer research organisations has hailed a golden age in prostate cancer drug discovery as for the fourth time in two years results are published finding a new drug can significantly extend ...
Cancer Aug 15, 2012 | 1 / 5 (1) | 1 |
Patients in early clinical trials of new-style targeted cancer therapies appear to have a much lower risk of the most serious side-effects than with traditional chemotherapy, according to a new analysis.
Cancer Aug 07, 2012 | not rated yet | 0
Women who are obese continue to have higher levels of oestrogen than women of normal weight even after treatment with hormone-suppressing drugs, raising the possibility that they might benefit from changes to their treatment.
Cancer Jul 16, 2012 | not rated yet | 0 |
A new drug combination could offer hope to children with neuroblastoma one of the deadliest forms of childhood cancer by boosting the effectiveness of a promising new gene-targeted treatment.
Cancer Jul 11, 2012 | 5 / 5 (1) | 0 |